BCL2 and lymphoid leukemia: Similarly, when apigenin was used in combination with cyclophosphamide there was a synergistic decrease on BCL2 gene expression in Jurkat lymphoid leukaemia cells only (Fig. 1A), when compared to the vehicle control and drugs alone, (P ≤ 0.05), with no further decrease seen in THP-1 cells when cyclophosphamide was combined with apigenin compared to cyclophosphamide alone (Fig. 1A).